ProPhase Labs, Inc. Accounts Receivable
ProPhase Labs, Inc. (PRPH) had Accounts Receivable of $1.54 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-19
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.54M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $1.54M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $1.54M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $3.28M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.54M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $1.54M 10-Q/A · filed 2026-07-09 | |
| 2025-12-31 | $1.54M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $3.28M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $20.09M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $20.20M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $20.06M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $31.64M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $32.94M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $35.12M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $35.81M 10-K · filed 2025-04-01 | $36.31M 10-K · filed 2024-03-29 |
| 2023-09-30 | $38.64M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $38.57M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $37.84M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $37.05M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $37.83M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $36.67M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $36.69M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $37.71M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $10.68M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $6.64M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $14.34M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $3.15M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $3.00M 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $1.93M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $1.21M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $2.01M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $1.48M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $738.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $788.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $2.97M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $1.05M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $1.36M 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $1.78M 10-Q/A · filed 2018-08-20 | |
| 2017-12-31 | $1.95M 10-K · filed 2019-03-26 | |
| 2017-09-30 | $1.11M 10-Q/A · filed 2018-08-20 | |
| 2017-06-30 | $1.83M 10-Q/A · filed 2018-08-20 | |
| 2017-03-31 | $3.41M 10-Q/A · filed 2018-08-20 | |
| 2016-12-31 | $5.77M 10-Q/A · filed 2018-08-20 | |
| 2016-09-30 | $3.83M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $1.80M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $2.69M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $4.00M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $2.77M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $1.25M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $3.47M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $5.84M 10-K · filed 2016-03-29 | |
| 2014-09-30 | $4.05M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $2.34M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $2.86M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $5.32M 10-K · filed 2015-03-27 | |
| 2013-09-30 | $4.45M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $1.13M 10-Q · filed 2013-08-13 | |
| 2013-03-31 | $3.08M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $5.41M 10-K · filed 2014-03-27 | |
| 2012-09-30 | $4.17M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $938.00K 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $2.54M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $3.22M 10-K · filed 2013-03-28 | |
| 2011-09-30 | $4.42M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $1.16M 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $4.82M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |